ARQT Sep 2024 5.000 call
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 09:30AM EDT. Market open.
Loading interactive chart…
- Zacks
AstraZeneca's (AZN) Imfinzi Meets Study Goal in Bladder Cancer
Data from a late-stage study shows that treatment with AstraZeneca's (AZN) Imfinzi plus chemotherapy before and after bladder removal surgery improves survival in patients.
- Zacks
FDA Expands argenx's (ARGX) Vyvgart Label to Treat Rare Disorder
Per argenx (ARGX), the label expansion to Vyvgart Hytrulo makes it the first FDA-approved medication with a novel mechanism of action to treat chronic inflammatory demyelinating polyneuropathy.
- Zacks
OVID Slumps 76% on Epilepsy Drug Failing Two Pivotal Studies
Two late-stage studies, which evaluated Ovid Therapeutics' (OVID) experimental drug for two forms of epilepsy, fail to meet their primary endpoints.
© 2024 Yahoo. All rights reserved.